Janux Therapeutics, Inc. Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Janux Therapeutics, Inc. (JANX) holds an ST Score of 56.2 out of 100 (B-), with its strongest factor being Profitability (A) and its weakest Growth (D-). Analysts rate JANX Buy across 16 ratings with a $28.25 average price target (+0.7% vs the current $16.59).
- Strongest
- ProfitabilityA
- Weakest
- GrowthD-
All factor grades
- ProfitabilityA
- Financial StrengthA-
- ValuationB+
- ForecastB
- MomentumB-
- SentimentC+
- GrowthD-
- Piotroski3/9
Contact
JANX stock: frequently asked questions
What is JANX's ST Score?
Janux Therapeutics, Inc. (JANX) has an ST Score of 56.2 out of 100, an overall grade of B-. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is JANX a buy, sell, or hold?
Wall Street's consensus rating on JANX is Buy based on 16 analyst ratings. Our own ST Score grades it B- (56.2/100). This is data, not investment advice — always do your own research.
What is JANX's valuation grade?
Janux Therapeutics, Inc. (JANX) earns a valuation grade of B+, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is JANX's growth grade?
Janux Therapeutics, Inc. (JANX) earns a growth grade of D-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is JANX's profitability grade?
Janux Therapeutics, Inc. (JANX) earns a profitability grade of A, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is JANX's financial strength grade?
Janux Therapeutics, Inc. (JANX) earns a financial strength grade of A-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for JANX?
The average analyst price target for Janux Therapeutics, Inc. (JANX) is $28.25 from 16 analysts, which is +0.7% versus the recent price of $16.59.
What is JANX's Piotroski score?
Janux Therapeutics, Inc. (JANX) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.